

ISIDOG

INTERNATIONAL SOCIETY
FOR INFECTIOUS DISEASES IN
OBSTETRICS AND GYNAECOLOGY



WELCOME TO



02nd ISIDOG CONGRESS

FINAL PROGRAM

VIENNA, AUSTRIA
OCT. 26th – 29th, 2017

Simultaneous
Translation in
German and
English



Good bacteria promotes women's health



02nd ISIDOG CONGRESS

TABLE OF CONTENTS

WELCOME WORDS	04
CONGRESS ORGANISATION	05
REGISTRATION INFORMATION	06
CONGRESS INFORMATION	08
GENERAL INFORMATION VIENNA	10
TRAVEL INFORMATION	12
SCIENTIFIC PROGRAM AT A GLANCE	14
SCIENTIFIC PROGRAM	16
POSTER INDEX / ABSTRACTS	28
LIST OF SPEAKERS, CHAIRS & AUTHORS	35
AUTHOR INDEX	36
SCIENTIFIC INFORMATION	38
OFFICIAL NETWORKING PROGRAM	39
EXHIBITION & SPONSORING	40
INDUSTRY SYMPOSIUM	41
FLOOR PLAN	42

Congress website

www.mondial-congress.com/isidog2017

02nd ISIDOG CONGRESS

WELCOME WORDS

It is our pleasure to welcome you to the 02nd ISIDOG Congress in Vienna hosted by the Austrian Commission of the European Society for Infectious Diseases (ESIDOG) and the International Society for Infectious Diseases (ISIDOG) in cooperation with the Austrian Society of Obstetrics and Gynaecology (OEGGG).

Our team has prepared a very interactive and stimulating program for all attendees, including an international schedule in English as well as a local part lectured in German. We offer opportunities to explore breakthroughs in research and daily clinical practice, to share creative and stimulating ideas, make valuable connections and obtain inspired perspectives from all members interested in the treatment of gynaecological infections. The plenary sessions feature presentations by experts across disciplines on a wide range of clinical and research topics. The four-day event will provide excellent networking opportunities and innovative learning experiences, highlighting the state-of-the-art, evidence-based developments in infectious diseases.

OUR GOALS FOR THE CONGRESS ARE:

- Participate in outstanding educational sessions and interactive debates.
- Collaborate with members of multinational teams to solve complex problems, reduce barriers and improve treatment standards.
- Preview the current technologies, products and services provided by numerous exhibitors.

We would like to welcome you to Vienna and make your stay in our picturesque city in the hub of Europe a magnificent one.

Sincerely,



A handwritten signature in blue ink.

Ljubomir Petricevic, MD
Congress President



A handwritten signature in blue ink.

Gilbert Donders, MD
President of ISIDOG



A handwritten signature in blue ink.

Herbert Kiss, MD, MBA
President of the ESIDOG Austria

02nd ISIDOG CONGRESS

CONGRESS ORGANISATION

Organising committee

Congress President:

Ljubomir Petricevic, MD

President of ISIDOG:

Gilbert Donders, MD

President of ESIDOG Austria:

Herbert Kiss, MD, MBA

in cooperation with



Important addresses

**Congress secretariat,
sponsoring &
commercial exhibition**

Mondial Congress & Events

Operngasse 20b

1040 Vienna, Austria

Tel.: +43 1 58804 172

Fax: +43 1 58804 185

isidog2017@mondial-congress.com

Organising & scientific secretariat

ESIDOG Austria,

Department of Obstetrics
and Gynaecology, MUV

Philipp Pappenscheller

Waehringerguertel 18-20

1090 Vienna, Austria

Tel.: +43 (0)1 40 400-28810

isidog2017vienna@esidog.at

www.esidog.at

Board Members

ISIDOG

INTERNATIONAL SOCIETY
FOR INFECTIOUS DISEASES IN
OBSTETRICS AND GYNAECOLOGY

ISIDOG EXECUTIVE BOARD

Gilbert GG Donders, president

Peter Greenhouse, vice president

Werner Mendling

Ljubomir Petricevic, scientific board chairman

Dace Rezeberga



ESIDOG AUSTRIA BOARD

Herbert Kiss, president

Christian Egarter, 1st vice president

Ljubomir Petricevic, 2nd vice president

Peter Husslein, 1st secretary

Elmar Joura, 2nd secretary

Ulrike Kaufmann, administrator

Klaus Reisenberger, treasurer

02nd ISIDOG CONGRESS

REGISTRATION INFORMATION

Registration Area

The Registration Area is located on the ground level of Palais Niederösterreich. The Mondial Congress & Events team will be pleased to help you with all inquiries regarding registration, congress materials, hotel accommodation and the networking program. Please do not hesitate to approach the team members if there is anything they can do to make your stay more enjoyable.

Opening Hours Registration Counter

Thursday, October 26 th , 2017	11:00-20:00
Friday, October 27 th , 2017	07:30-18:00
Saturday, October 28 th , 2017	08:00-17:00

Opening Hours Exhibitor Registration Counter & Exhibitor Service Desk

Thursday, October 26 th , 2017	09:00-20:00
Friday, October 27 th , 2017	07:30-18:00
Saturday, October 28 th , 2017	08:00-17:00

The registration counters can be reached onsite by calling +43 676 845 880 708

Registration Counters

Pre-Registered Delegates

Please have the confirmation letters sent by Mondial Congress & Events close at hand. If you still have an outstanding payment, you may settle your account in cash or by credit card (Visa, MasterCard, American Express, and Diners Club will be accepted). EURO (€) only.

Onsite Registration

For participants registering and paying their registration fees onsite.

You will need to fill out an onsite registration form. Payments will be accepted in cash or by credit card (Visa, MasterCard, American Express and Diners Club will be accepted). EURO (€) only.

02nd ISIDOG CONGRESS

REGISTRATION INFORMATION

Exhibitor Registration Counter & Exhibitor Service Desk

Exhibitors need to pick up their badge at the Exhibition Registration Desk in the Registration Area located on the ground floor of the congress venue.

Onsite Registration Fees

All prices are given in EUR (€).

OEGGG/ESIDOG/ISIDOG member	EUR 290,00
Non-member	EUR 390,00
OEGGG/ESIDOG/ISIDOG member student/resident*	EUR 90,00
Non-member student/resident*	EUR 190,00

* written confirmation necessary to verify your student/resident status

The registration fee includes:

- › Admission to all scientific and industry sessions
- › Admission to the commercial exhibition
- › Congress materials (congress bag, final program, badge)
- › Certificate of Attendance
- › Admission to the Opening Ceremony & Welcome Reception on Thursday, October 26th, 2017

02nd ISIDOG CONGRESS

CONGRESS INFORMATION

Art Exhibition

The expositions of Axel Schaefer presents portraits of infectious agents relevant in obstetrics and gynecology and explores the hidden beauty of these common public enemies, we may meet in our daily work. Portraits will be presented in „Foyer C“ and „Gotisches Zimmer“



herpes Simplex virus

Car Parking

It is highly recommended to use public transportation as there are no parking spots available at the congress venue. Within the city center of Vienna, parking charges apply. The following car parks are nearby the congress venue:
WiPark Garage Freyung: Freyung 4, A-1010 Vienna (2 min walking distance)
Parkgarage Am Hof: Am Hof 1, A-1010 Vienna (4 min walking distance)
Parkgarage Rathauspark: Rathausplatz 6, A-1010 Vienna (8 min walking distance)

Cloakroom

A cloakroom and luggage storage facilities are available on the ground floor next to the registration counter.

Congress Language

The official language of the congress is English. Simultaneous Translation into German will be offered on Friday, October 27th and Saturday, October 28th, 2017. On Thursday, October 26th, 2017 all German lectures will be translated into English.

Congress Staff

The Mondial Congress & Events team will be at your service at the registration counter. Do not hesitate to approach them with queries – they will gladly assist you.

Congress Venue

Palais Niederösterreich,
Herrengasse 13, 1010 Vienna, Austria
www.palais-niederoesterreich.at



02nd ISIDOG CONGRESS

CONGRESS INFORMATION

DFP Accreditation

The scientific program of the 2nd ISIDOG (ID 578468) is accredited by the Austrian Medical Chamber with 33 DFP credit points.



International delegates have to convert the Austrian credit points (DFP) into country-specific credit points.

First Aid

In case of need, please contact the staff at the registration counter.

Internet

WiFi is available throughout the congress venue.

Network: PalaisNOE_free

Password: no password

Liability

Mondial Congress & Events shall act as mediator only and cannot be held responsible for any loss incurred or any damage inflicted on persons or objects irrespective of whatsoever cause. The liability for transport and other service companies shall not be affected by the above. Only written agreements shall be valid. The place of jurisdiction shall be Vienna.

Name Badge & Certificate of Attendance

You will receive a personalised badge when collecting your registration documents. Throughout the congress, this badge must be clearly visible at all times and grants access to the scientific sessions, commercial exhibition and networking events included in the registration fee. Your certificate of attendance will be included in your congress materials available at the registration counter.

Smoking

We have a strict non-smoking policy at the 02nd ISIDOG CONGRESS. Therefore smoking inside the congress venue is prohibited. Smoking areas can be found in front of the main entrance and on the balcony (on the 1st floor).

02nd ISIDOG CONGRESS

GENERAL INFORMATION VIENNA

About Vienna

Whether this is your first visit to Vienna or you have been here before – this city always finds ways to surprise and delight you. Just take in its atmosphere, which is rich in history and tradition, yet also fresh and upbeat. The city centre is a small universe in itself: discover historical palaces face to face with modern facades, elegant boutiques next to popular fashion stores, and antique shops lining up across from stylish designer hotspots.

Art permeates Vienna's very essence – get a feel of it during a city walking tour, or while visiting one of Vienna's many museums. Must-sees include the Kunsthistorisches Museum, Albertina and the museums located in the trendy Museumsquartier (MQ). Sights not to be missed are St. Stephen's Cathedral right in the heart of the city, Schönbrunn palace, and the Giant Ferris Wheel at the "Prater" fairground. Fans of classical music and opera lovers may jump at a chance to spend an evening at the Staatsoper or the Musikverein. More modern fare can be found at Vienna's jazz bars, world music pubs and dance clubs. When it comes to food, you should definitely try famous Austrian dishes such as "Wiener Schnitzel" (breaded escalope of veal) or "Tafelspitz" (prime boiled beef). Your stay isn't complete without treating yourself to coffee and a slice of cake at one of Vienna's coffeehouses, or trying some organic ice cream.

If you are interested in sightseeing tours or more touristic information about Vienna, please visit the registration counter. Useful information on Vienna as well as an event calendar to be found online at www.wien.info.

Currency and Banks

The official currency in Austria is EURO (€).

Banking hours in general are Monday, Tuesday, Wednesday, Friday 08:00-12:30 and 13:30-15:00, Thursday 08:00-12:30 and 13:30-17:30. ATMs are located outside most banks, cash can be withdrawn there 24/7. National and foreign Maestro cards (cash cards) as well as Mastercard, AMEX, Visa and Diners are accepted.

Electricity & Time

The main voltage in Austria is 220V. Vienna is in the Central European Time Zone, Greenwich Mean Time (GMT) +1hour.

02nd ISIDOG CONGRESS

GENERAL INFORMATION VIENNA

Shopping

Shops are usually open from 10:00 – 19:00 from Monday to Friday and from 10:00 – 18:00 on Saturday. On Sunday shops are usually closed except in the old town. Grocery stores already open around 8:00 during weekdays.

Tipping

Service is usually included in the prices in bars and restaurants. Tips are always welcome and usually 10%.

Useful Telephone Numbers

Ambulance:	144
Police:	133
Fire Brigade:	122
Taxi:	+43 1 31 300
	+43 1 40 100

Passport and Visa

Please check passport and visa requirements in due time before your departure. Three-month tourist visas are issued by Austrian embassies or consulates. They can take a while to be processed, so leave enough time before departure to apply. Fees vary depending on your nationality. There are no entry requirements or restrictions on EU nationals visiting Austria.

Insurance

Delegates are advised to arrange health and accident insurance prior to travelling to the congress. The congress organisers will not assume any responsibility for accidents, losses or damages, as well as for delays or modifications in the program, caused by unforeseen circumstances. No claims for indemnification from the organisers shall arise for contractors or participants in case of cancellation, for any reason, of the entire Congress.

02nd ISIDOG CONGRESS

TRAVEL INFORMATION

Access by Plane

More than 70 international airlines offer scheduled services to Vienna. There are several daily flights between Vienna and the main European capitals and business centres. Austrian Airlines, the country's flag carrier, connects 116 cities worldwide with Vienna and offers modern aircrafts and excellent service. Vienna International Airport at Schwechat, 19 km (12 miles) from the city centre, is state-of-the-art in every respect.

Access by Car/Coach

Austria's expressway network reaches right into Vienna, allowing a comfortable and convenient trip to Vienna by car or coach from any point on the European continent.

Access by Train

Vienna occupies a hub position in Europe's international railway network. Intercity and international express trains are connecting cities of all parts of Austria and all major European destinations with Vienna.

From the Airport to the City Centre and Vice Versa

Bus: At 20-minute intervals, the Vienna Airport Lines depart between 05:30 and 24:00 daily. Cost: approx. € 8,-. Duration: approx. 20–30 min.

Train: The urban railway leaves at 30-minute intervals between 05:00 and 22:00 daily. Cost: approx. € 4,-. Duration: approx. 30–40 min.

Car: Take Autobahn A4 from the Airport to Vienna. The city centre is signposted.

CAT: The City Airport Train runs at 30-minute intervals from 06:05 to 23:00 daily from the airport to train station "Landstrasse/Wien Mitte".
Cost: € 11,- one way (including return ticket EUR 19,00).
Duration: approx. 16 min.

02nd ISIDOG CONGRESS

GENERAL INFORMATION VIENNA

Public Transportation in Vienna

Palais Niederösterreich (U3 Herrengasse) as well as all hotels can easily be reached using Vienna's efficient and modern public transport network of underground lines, trams and busses. Depending on the line in question, hours of operation are between 5:00 and 00:30 daily. On weekends, the metro operates throughout the night with 7- to 15-minute intervals.

Prices

Single Trip Ticket Vienna	EUR 2,20
24 Hours	EUR 7,60
48 Hours	EUR 13,30
72 Hours	EUR 16,50

Public transportation tickets are available at Vienna Transport Authority's ticket offices, as well as at the ticket machines in all underground stations.

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM AT A GLANCE

Thursday, 26 th October, 2017			
LANDTAGSSAAL		PRÄLATENSAAL	
13:00 - 15:30	ESIDOG German lectures		
15:30 - 16:00	BREAK	15:00-18:00	ISIDOG Country manager meeting
16:00 - 18:10	ESIDOG German lectures II		
18:15 - 19:30	Opening ceremony & Keynote lecture		
19:30	Welcome reception (exhibition area)		

Friday 27 th October, 2017			
LANDTAGSSAAL		PRÄLATENSAAL	
08:30 - 10:10	Main Session 1 - STI		
10:10 - 10:30	BREAK		
10:30 - 12:10	Main Session 2 - HPV		
12:15 - 13:15	Industry-supported symposium p. 41		
13:30 - 15:00	Free Communication 1 - HPV	Free Communication 2 - General Infections, Probiotics	
15:00 - 15:30	BREAK		
15:30 - 17:20	Main Session 3 - Infection in pregnancy		

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM AT A GLANCE

Saturday 28 th October, 2017		
	LANDTAGSSAAL	PRÄLATENSAAL
08:30 - 10:10	Main Session 4 - Vulvovaginitis I	
10:10 - 10:30	BREAK	
10:30 - 12:10	Main Session 5 - Vulvovaginitis II	
12:15 - 13:15	Industry-supported symposium p. 41	
13:30 - 15:00	Free Communication 3 - Vulvovaginitis	Free Communication 4 - Pregnancy
15:00-17:00	Main Session 6 - Probiotics and woman´s health	
19:30	Networking Evening I Emperor´s lodge	
Sunday 29 th October, 2017		
09:00 - 11:00	ISIDOG board meeting I Hotel Regina	

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Thursday 26 th October, 2017		
ESIDOG GERMAN LECTURE 1 Chair: <i>Kiss H. (AT), Petricevic L. (AT)</i> Landtagssaal	13:00	Eröffnungsworte <i>Kiss H. (AT), Petricevic L. (AT)</i>
	13:10	Probiotika in der Frauenheilkunde — Update <i>Petricevic L. (AT)</i>
	13:40	Vaginale Candidose <i>Mendling W. (DE)</i>
	14:10	Cytomegalie-Virus — Leitlinie der optimalen Therapie <i>Kiss H. (AT)</i>
	14:40	Virusinfektionen <i>Redlberger-Fritz M. (AT)</i>
	15:10	Diskussion
15:30 - 16:00 BREAK		
ISIDOG COUNTRY MANAGER MEETING <i>by Invitation only</i> Prälatensaal	15:00 to 18:00	Chair: <i>Donders G. (BE), Petricevic L. (AT)</i>

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Thursday 26 th October, 2017		
ESIDOG GERMAN LECTURE 2 Chair: <i>Kiss H. (AT), Farr A. (AT)</i> Landtagssaal	16:00	Mikroskopie von gynäkologischen Infektionen <i>Farr A. (AT)</i>
	16:30	HPV-Prävention <i>Joura E. (AT)</i>
	17:00	Harnwegsinfektion der Frau <i>Vossen M. (AT)</i>
	17:30	Diskussion
OPENING CEREMONY Landtagssaal	18:15	Donders G. (BE) — <i>ISIDOG President</i> Petricevic L. (AT) — <i>Congress President</i>
KEYNOTE LECTURE Landtagssaal	18:30	Art of infection <i>Schäfer A.* (DE)</i>
WELCOME RECEPTION	19:30	Exhibition area

**1950: born in Berlin 1971-80 Studies of Design and Art at the Berlin Art school and Biology and Medicine at the Free University Berlin 1981-1984 Assistant at the institute of Molecular Biology FU Berlin and working as a gallerist 1985-1991 Department of OB-GYN at the University Hospital FU Berlin 1992-2015 Attending physician at the Charité Berlin 2015- Consultant for STI and Laboratory Investigations*



02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Friday, October 27th, 2017

MAIN SESSION 1 STI

Chair: *Donders G. (BE),
Sobel J. (US)*

Landtagssaal

08:30	Herpes genitalis: new IUSTI/ISIDOG guidelines <i>Clarke E. (UK)</i>
08:50	Trichomonas is it forgotten? <i>Ruban K. (BE)</i>
09:10	Male factor as a reason for vaginal Dysbiosis <i>Mandar R. (EE)</i>
09:30	Chlamydia vaccination, trick or treat? <i>Stary G. (AT)</i>
09:50	BV as STI <i>Sobel J. (US)</i>

10:10 - 10:30 BREAK

MAIN SESSION 2 HPV

Chair: *Joura E. (AT),
Greenhouse P. (UK)*

Landtagssaal

10:30	HPV- screening — state of the art <i>Meijer Ch. (NL)</i>
10:50	HPV vaccination — the Nordic experience <i>Paavonen J. (FI)</i>
11:10	The ninevalent HPV vaccine <i>Joura E. (AT)</i>
11:30	HPV in semen impact on fertility <i>Depuydt Ch. (BE)</i>
11:50	Gender neutral HPV vaccination — pros and cons <i>Greenhouse P. (UK)</i>

INDUSTRY-SUPPORTED SYMPOSIUM

page 41

12:15 - 13:15

Landtagssaal

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Friday, October 27th, 2017

FREE COMMUNICATION 1 HPV

Chair: *Depuydt Ch. (BE),
Paavonen J. (FI)*

Landtagssaal

13:30

OC01- Infectious versus clonal high-risk human Papillomavirus (HPV) DNA prevalence in pregnant women *Christophe Depuydt (BE)*

OC02 - Influence of age on histologic outcome of cervical intraepithelial neoplasia: results from a large cohort, systematic review and meta-analysis *Christine Bekos (AT)*

OC03 - Correlation between Human Papillomavirus and premature birth *Nicolae Suci (RO)*

OC04 - Association between multiple HPV infection, HPV E6/E7 expression and cervical precancerous lesions severity *Irina Jermakova (LV)*

P01 - HPV and human reproduction *Nicolae Suci (RO)*

P02 - Comparison of liquid based and conventional Lishman stained cervical cytology *Jana Zozzika (LV)*

P03 - The HPV prevalence and type distribution in vulvar cancers in Austria *Lisa Gensthaler (AT)*

P04 - Vaginal flora changes and HPV infection association with abnormal cervical cytology *Olga Plisko (LV)*

P05 - HPV infection in pregnancy *Mihaela Bot (RO)*

P06 - Follow-up of patients after radical trachelectomy for cervical carcinoma *Elvira Bratila (RO)*

P06a - *WITHDRAWN*

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Friday, October 27th, 2017

FREE
COMMUNICATION 2
GENERAL
INFECTIONS,
PROBIOTICS

Chair: *Mendling W. (DE),
Farr A. (AT)*

Prälatensaal

13:30

OC05 - Influence of orally administered probiotics on vaginal microbiota in women with breast cancer during chemotherapy: A randomized placebo-controlled double-blinded pilot study

Julian Marschale (AT)

OC06 - The use of VGN probiotic vaginal cream for the treatment of acute Candida vaginitis: A proof of concept study *Gert Bellen (BE)*

OC07 - The female urinary microbiome and its contribution to lower urinary tract symptoms – a review *Nikolaus Veit-Rubin (AT)*

P07 - Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women – a double-blind, randomized, controlled clinical pilot trial *Jürgen Schrezenmeir (DE)*

P08 - Incidence of endometritis post partum at the tertiary institution *Ana Mijailovic (RS)*

P09- Prevalence of sexually transmitted infections (STIS) in a cohort of HIV-positive women
Joana Xavier (PT)

P10 - Pelvic actinomycosis mimics ovarian cancer – A case report *Dunja Kokanov (RS)*

P11 - The „VG-Test“ as diagnostic tool at point of care, or at bedsides in hospitals.
Moshe Golan (IS)

P12 - Vaginal semisolid products: technological performance and in vitro evaluation under a safety perspective *Ana Palmeira-de-Oliveira (PT)*

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Friday, October 27th, 2017

P13 - Formulation, technological characterization and in vitro toxicity of a new vaginal estriol cream (VEC)

Ana Palmeira-de-Oliveira (PT)

P14 - Peritoneal tuberculosis in immunocompetent reproductive-aged patients. *Diana Mihai (RO)*

15:00 - 15:30 BREAK

MAIN SESSION 3 INFECTION IN PREGNANCY

Chair: *Kiss H. (AT),
Ugwumadu A. (UK)*

Landtagssaal

15:30 Prediction of maternal cytomegalovirus serostatus in early pregnancy

Kiss H. (AT)

15:50 Asymptomatic vaginal infections and PTD

Farr A. (AT)

16:10 Con's GBS screenings in pregnancy

Ugwumadu A. (UK)

16:30 Pro's GBS screening in pregnancy

Martinez de Tejada B. (CH)

16:50 Zika Virus: significance in pregnancy

Surbek D. (CH)

17:10 Mycoplasma guidelines

Donders G. (BE)

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Saturday, October 28th, 2017

MAIN SESSION 4 VULVOVAGINITIS 1

Chair: *Mendling W. (DE),
Vieira Baptista P. (PT)*

Landtagssaal

08:30	Molecular diagnosis of bacterial vaginitis/osis <i>Ivanova-Rumyantseva T. (RU)</i>
08:50	Genetics of candida vulvovaginitis <i>ten Oever J. (NL)</i>
09:10	Vagina: a hostile milieu for lactobacilli <i>Palmeira de Oliveira A. (PT)</i>
09:30	Influence of teaching gynecological infectiology and microscopy on diagnostic performance <i>Mendling W. (DE)</i>
09:50	Genito urinary syndrome of menopause: real or fiction? <i>Vieira Baptista P. (PT)</i>

10:10 - 10:30 BREAK

MAIN SESSION 5 VULVOVAGINITIS 2

Chair: *Rezeberga D. (LV),
Hay P. (UK)*

Landtagssaal

10:30	Vaginal atrophy in breast cancer <i>Donders G. (BE)</i>
10:50	Status of vaccination studies <i>Mendling W. (DE)</i>
11:10	Bacteriophages for BV treatment <i>Hay P. (UK)</i>
11:30	Modern treatment of BV <i>Larsson P.G. (SE)</i>
11:50	Vaginal interventions, should we use antibiotics? <i>Rakic S. (RS)</i>

INDUSTRY-SUPPORTED SYMPOSIUM

page 41

12:15 - 13:15

Landtagssaal

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Saturday, October 28th, 2017

FREE
COMMUNICATION 3
VULVOVAGINITIS

Chair: *Larsson P.G. (SE),
Vieira Baptista P. (PT)*

Landtagssaal

13:30

OC08 - Asymatic Bacterial Vaginosis: a myth or reality? A cross-sectional investigation to assess the prevalence and risk factors in Flanders.

Gert Bellen (BE)

OC09 - rRNA Miseq sequencing and qPCR show clearly different microbiome profiles in bacterial vaginosis and aerobic vaginitis

Eline Oerlemans (BE)

OC10 - Lactobacillus gasseri-dominated microbiome is associated with increased cervicovaginal bacterial load. *Camila Marconi (BR)*

P15 - Oral VT-1161 is Highly Effective and Safe in Patients with Recurrent Vulvovaginal Candidiasis—Results from a Multicenter Phase 2b Study

Stephen Brand (US)

P16 - Influence of extra-vaginal site colonization with *Candida* sp. on the response to individualised fluconazole maintenance therapy in women with Recurrent *Candida* Vulvo-Vaganitis

Gilbert Donders (BE)

P17 - Is sensitization to atopic reaction related to non-response to fluconazole maintenance therapy for Recurrent *Candida* Vulvo-Vaganitis (RCVV)?

Svitrigaile Grinceviciene (BE)

P18 - Characterization of the vaginal microbiome of healthy reproductive-aged Brazilian women

Camila Marconi (BR)

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Saturday, October 28th, 2017

FREE COMMUNICATION 3 VULVOVAGINITIS

Chair: *Larsson P.G. [SE],
Vieira Baptista P. [PT]*

Landtagssaal

13:30

P19 - Are BV pathologic core able to downregulate β defensins production to escape innate immunity?

Nathalia Mayumi Noda-Nicolau [BR]

P20 - Posterior vestibulectomy in the treatment of localized provoked vulvodynia — A long-term follow-up study *Päivi Tammola [FI]*

P21 - Wet mount characterization of the vaginal flora of women with HIV

Pedro Vieira-baptista [PT]

P22 - Non-response to maintenance treatment for Recurrent Vulvovaginal Candidosis (RCVV) is not related to the impaired glucose metabolism

Svitrigaile Grinceviciene [BE]

FREE COMMUNICATION 4 PREGNANCY

Chair: *Kiss H. [AT],
Surbek D. [CH]*

Landtagssaal

13:30

OC11 - Cervico-vaginal placental alpha-microglobulin-1 (PAMG-1) combined with cervical length accurately predict preterm birth in women with threatened preterm labor *Anda-Petronela Radan [CH]*

OC12 - Pregnant women with cytomegalo virus infection — obstetrical and neonatal outcome

Ana Isabel Ribeiro [PT]

P23 - Management of pregnancy and birth in HIV positive mothers – 20 years of experience in „Panait Sirbu” Clinical Hospital of Obstetrics & Gynecology, Bucharest *Elvira Bratila [RO]*

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Saturday, October 28th, 2017

13:30

P24 - Seroprevalence of Anti-Chlamydia trachomatis IGM in neonatal respiratory tract infections in Hungary, 2008-2016 *Eszter Balla (HU)*

P25 - Distribution of conjunctival Chlamydia trachomatis genotypes in ophthalmia neonatorum in Hungary, 2008-2016 *Eszter Balla (HU)*

P26 - Genital bacterial infection, potential cause of preterm delivery *Mirjana Bogavac (RS)*

P27 - Two cases of preterm premature rupture of membranes (pPROM) and preterm birth with different outcome: still a challenge for clinical management *Veronica Falcone (AT)*

P28 - Is bacterial surveillance of the upper and lower respiratory tract important in pediatric primary dyskinesia patients? *Veronica Falcone (AT)*

P29 - Evaluation of the vaginal flora in pregnant women with opioid-maintenance therapy: a matched case-control study *Alex Farr (AT)*

P30 - Late Onset Candida Colonization and Preterm Birth *Iris Holzer (AT)*

P31 - Risk of vaginal infections at early gestation in patients with diabetic conditions: a retrospective cohort study *Julian Marschalek (AT)*

P32 - Prevalence and characteristics of active hepatitis B in pregnant women in Switzerland – a survey from two sites *Beatrice Mosimann (CH)*

P33 - How reliable are WBC count and CRP to monitor for intra-amnionic infection? *Gaba Aulona (AT)*

02nd ISIDOG CONGRESS

SCIENTIFIC PROGRAM

Saturday, October 28 th , 2017		
MAIN SESSION 6 PROBIOTICS AND WOMAN'S HEALTH Chair: <i>Petricevic L. (AT), Lamont R. (UK)</i> Landtagssaal	15:00	Probiotics as an option, from vaginal to oral <i>Petricevic L. (AT)</i>
	15:20	Improvement of BV treatment by use of probiotics <i>Lamont R. (UK)</i>
	15:40	Could we prevent cystitis using probiotics? <i>De Seta F. (IT)</i>
	16:00	Vaginal yeast and interaction with probiotic strains <i>Oerlemans E. (BE)</i>
	16:20	Is that all Probiotic, are all bacteria probiotics? <i>Domig K. (AT)</i>
NETWORKING EVENING	19:30	Emperor's lodge Location: Kaiserloge, Galopprennbahn Freudenau, Freudenau 65, 1020 Vienna
Sunday, October 29 th , 2017		
ISIDOG BOARD MEETING Chair: <i>Donders G. (BE)</i> Hotel Regina, Rooseveltplatz 15, 1090 Wien		
ISIDOG BOARD	09:00	Summary and strategy
	10:00	New Projects
ROUND TABLE	11:00	Round table discussion about prevalence vaginal infections in Europe ESC questionnaire

Varitect® CP

Humanes VZV-Hyperimmunglobulin
zur intravenösen Anwendung



Varitect® CP enthält 25 IE/ml Antikörper gegen Varizella-Zoster-Virus.

Die Zulassung umfasst die Varizellen-Prophylaxe nach Exposition bei

- **Schwangeren mit negativem VZV-Immunstatus, Neugeborenen und Frühgeborenen mit negativem oder unbekanntem VZV-Immunstatus,**
- **immunsupprimierten Erwachsenen und Kindern ohne Varizellen-Anamnese und/oder negativem VZV-Immunstatus**

Fachkurzinformation. Bezeichnung des Arzneimittels: Varitect® CP 25 I.E./ml Infusionslösung. **Qualitative und quantitative Zusammensetzung:** Varizella-Zoster-Immunglobulin vom Menschen. 1 ml Lösung enthält: Plasmaproteine vom Menschen 50 mg, davon Immunglobulin G (IgG) ≥ 96 %, Antikörpergehalt gegen Varizella-Zoster-Virus 25 I.E. Verteilung der IgG-Subklassen (Näherungswerte): IgG1 62%, IgG2 33%, IgG3 3 %, IgG4 2 %. Der Höchstgehalt an Immunglobulin A (IgA) beträgt 2 mg/ml. Hergestellt aus Plasma menschlicher Spender. Vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1. **Anwendungsgebiete:** Varizellen-Prophylaxe nach Exposition bei Schwangeren mit negativem VZV-Immunstatus bis zum frühen dritten Trimester. Neugeborenen, deren Mütter 7 Tage vor bis 7 Tage nach der Geburt an Varizelleninfektion erkrankt sind. Neugeborenen von Müttern ohne Varizellen-Anamnese und/oder negativem Immunstatus. Frühgeborenen, die nach weniger als 28 Schwangerschaftswochen geboren wurden oder Neugeborenen mit niedrigem Geburtsgewicht. Erwachsenen und Kindern ohne Varizellen-Anamnese und/oder negativem Immunstatus, die eine immunsuppressive Therapie erhalten (wie Behandlung mit Steroiden, Zytostatika, Strahlenbehandlung), die vor kurzem eine Stammzelltransplantation erhielten oder die an einer angeborenen oder erworbenen Immundefizienz leiden und nicht mit Immunglobulinen substituiert werden. **Anwendungshinweise** für die Postexpositionsprophylaxe mit Varizella-Zoster-Immunglobulin (VZIG) sind dem österreichischen Impfplan (www.bmgf.gv.at) zu entnehmen. **Gegenanzeigen:** Überempfindlichkeit gegen die Wirkstoffe oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile. Überempfindlichkeit gegen Immunglobuline vom Menschen, insbesondere bei Patienten mit Antikörpern gegen IgA. **Liste der sonstigen Bestandteile:** Glycin, Wasser für Injektionszwecke. **Pharmakotherapeutische Gruppe:** Spezifische Immunglobuline, **ATC Code:** Jo6BB03, **HK:** 3 Jahre, **PG:** 5ml (125I.E.), 20ml (500I.E.). **Rezeptpflicht/Apothekenpflicht:** Rezept- und apothekenpflichtig, wiederholte Abgabe verboten. Z. Nr.: 2-00383. **Zulassungsinhaber:** Biotest Austria GmbH, 1050 Wien. **Weitere Informationen zu Dosierung, Art und Dauer der Anwendung, Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen, Schwangerschaft und Stillzeit, Nebenwirkungen, Überdosierung** entnehmen Sie bitte der veröffentlichten Fachinformation.

02nd ISIDOG CONGRESS

POSTER INDEX / ABSTRACTS

OC01 – Infectious versus clonal high-risk human Papillomavirus (HPV) DNA prevalence in pregnant women

Depuydt C¹, Verstraete L¹, Beert J^{1,4}, Vanden Broeck D¹, Bosmans E¹, Salembier G¹, Donders G^{2,3}

¹Aml, Sonic Healthcare Belgium, Antwerp, Belgium, ²Department of OB/Gyn Antwerp University, Antwerp, Belgium, ³Femicare vzw, Tienen, Belgium, ⁴Intermediate Structure Human Body Material, Sonic Healthcare Belgium, Antwerp, Belgium

OC02 – Influence of age on histologic outcome of cervical intraepithelial neoplasia: results from a large cohort, systematic review and meta-analysis

Bekos C¹, Grimm C¹, Joura E¹, Horvat R², Reinhaller A¹, Polterauer S¹

¹Medical University Vienna, Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology, Vienna, Austria, ²Medical University Vienna, Department of Pathology, Vienna, Austria

OC03 – Correlation between Human Papillomavirus and premature birth

Suciu N^{1,2}, Cretoi D^{2,3}, Suciu I², Bacalbasa N¹, Toader O²
¹Department of Obstetrics and Gynecology, Carol Davila

University of Medicine and Pharmacy, Bucharest, Romania, ²Alessandrescu-Rusescu National Institute for the Health of Mother and Child, Bucharest, Romania, ³Department of Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

OC04 – Association between multiple HPV infection, HPV E6/E7 expression and cervical precancerous lesions severity

Jermakova I¹, Rezeberga D^{1,2}, Eglite L¹, Liepniece-Karele I², Žodžika J^{1,2}, Plisko O^{1,2}, Kroiča J¹, Sivīņa D², Kunicina D²
¹Rīga Stradiņš University, Rīga, Latvia, ²Rīga East Clinical University Hospital, Rīga, Latvia

P01 – HPV and human reproduction

Suciu N^{1,2}, Dragodan V², Suciu I², Pop L², Toader O^{1,2}
¹Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ²Alessandrescu-Rusescu National Institute for the Health of Mother and Child, Bucharest, Romania

P02 – Comparison of liquid based and conventional Lishman stained cervical cytology

Berza N¹, Zodzika J², Grjunberga V³, Isajevs S⁴, Uspele

L², Senfelde I², Petroška D⁵
¹Latvian University, Riga Eastern Clinical University hospital, Riga, Latvia, ²Riga Stradins University, Riga Eastern Clinical University hospital, Riga, Latvia, ³Cytological department of Riga East University Clinical Hospital, Riga, Latvia, ⁴Pathology department of Riga East University Clinical Hospital, Riga, Latvia, ⁵Cytopathology Department, National Center of Pathology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania

P03 – The HPV prevalence and type distribution in vulvar cancers in Austria.

Gensthaller L¹, Pils S¹, Stani J¹, Alemany L², Horvat R¹, Polterauer S¹, de Sanjose S², Joura E¹

¹Medical University of Vienna, Departement for Gynecology and Obstetrics, Wien, Austria, ²Catalan Institute of Oncology, Barcelona, Spain

P04 – Vaginal flora changes and HPV infection association with abnormal cervical cytology

Plisko O^{1,2}, Jermakova I^{1,2}, Rezeberga D^{1,2}, Zodzika J^{1,2}, Kroica J², Eglite L², Sivina D¹, Kunicina D¹
¹Rīga East Clinical University Hospital, Riga, Latvia, ²Rīga Stradins University, Riga, Latvia

02nd ISIDOG CONGRESS

POSTER INDEX / ABSTRACTS

P05 – HPV infection in pregnancy

Boț M¹, Vladareanu R¹, Vladareanu S¹

¹UMF Carol Davila

P06 – Follow-up of patients after radical trachelectomy for cervical carcinoma

Mitran M^{1,2}, Bratila E^{1,2}, Bratila P², Bohaltea R^{1,3}, Velicu O², Comandasu D^{1,2}

¹„Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania, ²„Panait Sirbu” Clinical Hospital of Obstetrics & Gynecology, Bucharest, Romania, ³Bucharest Emergency University Hospital, Bucharest, Romania

P06a – WITHDRAWN

OC05 – Influence of orally administered probiotics on vaginal microbiota in women with breast cancer during chemotherapy: A randomized placebo-controlled double-blinded pilot study

Marschalek J¹, Farr A¹, Marschalek M¹, Domig K², Kneifel W², Singer C¹, Kiss H¹, Petricevic L¹

¹Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna, Austria,

²Department of Food Science and Technology, BOKU – University of Natural Resources and Life Sciences, Vienna, Austria

OC06 – The use of VGN probiotic vaginal cream for the treatment of acute Candida vaginitis: A proof of concept study.

Donders G^{1,2}, Bellen G¹, Oerlemans E³, Claes I^{3,4}, Ruban K¹, Wuyts S³, Wittouck S³, Lebeer S³

¹Femicare, Clinical Research for Women, Tienen, Belgium,

²University hospital of Antwerp, department of Gynaecology and Obstetrics, Antwerp, Belgium, ³University of Antwerp, department of Bioscience Engineering, research group Environmental Ecology and Microbiology, Antwerp, Belgium, ⁴YUN NV, Aartselaar, Belgium

OC07 – The female urinary microbiome and its contribution to lower urinary tract symptoms – a review

Veit-Rubin N¹, Schneeweiss-Friedl J¹, Koch M¹, Umek W¹

¹Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria

P07 – Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women – a double-blind, randomized, controlled clinical pilot trial

Linnerth B¹, Arendarski P², Kneifel W³, Papazova E⁴, Schrezenmeir J^{4,5}, Pannenbeckers A⁴, Domig K³, Laue C⁴, Liesegang A⁴, Petricevic L⁶

¹Dairyfem, Tuchlauben 18/12, 1010 Vienna, Austria, ²LADR, Lauenburger Str. 67, 21502 Geesthacht, Germany, ³BOKU – University of Natural Resources and Life Sciences, Vienna, Austria, ⁴Clinical Research Center, Schauenburgerstraße 116, 24118 Kiel, Germany, ⁵University Medicine, Langenbeckstraße 1, 55131 Mainz, Germany, ⁶Department of Obstetrics and Fetomaternal Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

P08 – Incidence of endometritis post partum at the tertiary institution

Mijailovic A¹, Novakovic S¹, Mилоvanovic Z¹, Zecevic N^{1,2}, Rakic S^{1,2}, Nikolic M¹, Mihajlovic S^{1,2}, Vangelov M, Petricevic L³

¹“Gynecology And Obstetrics Clinic Narodni Front”, Belgrade, Serbia, ²Medical School University of Belgrade, Belgrade, Serbia, ³Medizinische Universität Wien, Vienna, Austria

02nd ISIDOG CONGRESS

POSTER INDEX / ABSTRACTS

P09 – Prevalence of sexually transmitted infections (STIS) in a cohort of HIV-positive women

Donders G^{2,3,4}, Xavier J¹, Vieira-Baptista P¹, Lima-Silva J¹, Malheiro F¹, Melo C¹, Falcão V¹, Beires J¹

¹Centro Hospitalar de São João, Porto, Portugal,

²Antwerp University Hospital, Antwerp, Belgium, ³Regional Hospital Heilig Hart, Tienen, Belgium, ⁴Femicare, Clinical Research for Women, Tienen, Belgium

P10 – Pelvic actinomycosis mimics ovarian cancer – A case report

Davidovic-Grigoraki M¹, Mandic A¹, Solajic N¹, Kokanov D¹

¹Oncology Institute of Vojvodina, Novi Sad, Serbia

P11 – The “VG-Test” as diagnostic tool at point of care, or at bedsides in hospitals.

Golan M¹

¹3QBD Ltd, Arad, Israel

P12 – Vaginal semisolid products: technological performance and in vitro evaluation under a safety perspective

Machado R^{1,2}, Palmeira-de-Oliveira A^{1,2}, Martinez-de-Oliveira J^{1,3}, Palmeira-de-Oliveira R^{1,2,4}

¹University of Beira Interior, Health Sciences Research Center (CICS-UBI), Covilhã, Portugal, ²Labfit - Health Products Research and

Development, Lda, Covilhã, Portugal, ³Child and Woman's Health Department, CHCB - Cova da Beira Hospital Center, Covilhã, Portugal, Covilhã, Portugal, ⁴Pharmacy Department, CHCB - Cova da Beira Hospital Center, Covilhã, Portugal, Covilhã, Portugal

P13 – Formulation, technological characterization and in vitro toxicity of a new vaginal estriol cream (VEC)

Machado R^{1,2}, Palmeira-de-Oliveira A^{1,2}, Martinez-de-Oliveira J^{1,3}, Palmeira-de-Oliveira R^{1,2,4}

¹University of Beira Interior - Health Sciences Research Center (CICS-UBI), Covilhã, Portugal, ²Labfit - Health Products Research and Development, Lda, Covilhã, Portugal, ³Child and Woman's Health Department, CHCB - Cova da Beira Hospital Center, Covilhã, Portugal, Covilhã, Portugal, ⁴Pharmacy Department, CHCB - Cova da Beira Hospital Center, Covilhã, Portugal

P14 – Peritoneal tuberculosis in immunocompetent reproductive-aged patients.

MIHAI D¹, COMANDAȘU D¹, BRĂȚILĂ E^{1,2}, MITRAN M^{1,2}, CÎRȘTOIU M^{2,3}, BERCEANU C⁴, MEHEDIȚU C²

¹Clinical Hospital Of Obstetrics And Gynecology “prof. Dr. Panait Sârbu”, Bucharest (romania), Bucharest, Romania, ²„Carol Davila” University

of Medicine and Pharmacy, Department of Obstetrics and Gynecology, Bucharest, Romania, ³University Emergency Hospital, Department of Obstetrics and Gynecology, Bucharest, ROMANIA, ⁴Craiova University of Medicine and Pharmacy, Obstetrics Gynecology, Craiova, Romania

OC08 – Asymptomatic Bacterial Vaginosis: a myth or reality? A cross-sectional investigation to assess the prevalence and risk factors in Flanders.

Bellen G^{1,2}, Meynendonckx S², Jacquemyn Y³, Donders G^{1,2,3,4}

¹Femicare vzw, Research for Women, Tienen, Belgium, ²University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium, ³University hospital Antwerp, Department of gynaecology, Antwerp, Belgium, ⁴Regional hospital, H. Hart Tienen, Department of gynaecology, Tienen, Belgium

OC09 – rRNA Miseq sequencing and qPCR show clearly different microbiome profiles in bacterial vaginosis and aerobic vaginitis

Oerlemans E¹, Wuyts S¹, Bellen G², Wittouck S¹, Claes I¹, Donders G², Lebeer S¹

¹University of Antwerp, department of Bioscience Engineering, research group Environmental Ecology and Microbiology, Antwerp, Belgium, ²University hospital

02nd ISIDOG CONGRESS

POSTER INDEX / ABSTRACTS

of Antwerp, department of Gynaecology and Obstetrics, Antwerp, Belgium

OC10 – Lactobacillus gas-seri-dominated microbiome is associated with increased cervicovaginal bacterial load.

Marconi C^{1,2}, Novak J¹, Ferreira C¹, Golim M³, Silva M¹

¹São Paulo State University, Botucatu Medical School, Department of Pathology, Botucatu, Brazil, ²Federal University of Paraná, Sector of Biological Sciences, Department of Basic Pathology, Curitiba, Brazil, ³São Paulo State University, Botucatu Medical School, Blood Center, Botucatu, Brazil

P15 – Oral VT-1161 is Highly Effective and Safe in Patients with Recurrent Vulvovaginal Candidiasis — Results from a Multicenter Phase 2b Study

Brand S¹, Degenhardt T¹, Person K¹, Sobel J², Nyirjesy P³, Schotzinger R¹, Tavakkol A¹

¹Viamet Pharmaceuticals, Durham, United States, ²Wayne State University School of Medicine, Detroit, United States, ³Drexel University College of Medicine, Philadelphia, United States

P16 – Influence of extra-vaginal site colonization with Candida sp. on the response to individualised fluconazole maintenance therapy in women with

Recurrent Candida Vulvovaginitis

Bellen G¹, Grinceviene S^{1,2}, Ruban K¹, Donders G^{1,3}

¹Femicare vzw, Tienen, Belgium, ²University Institute of Biotechnology, Department of Bio-thermodynamics and Drug Design, Vilnius, Lithuania, ³Department of OB/Gyn, Antwerp University, Antwerp, Belgium

P17 – Is sensitization to atopic reaction related to non-response to fluconazole maintenance therapy for Recurrent Candida Vulvovaginitis (RCVV)?

Donders G^{1,2}, Grinceviene S^{1,3}, Bellen G¹, Jaeger M⁴, ten Oever J⁴, G. Netea M⁴

¹Femicare vzw, Tienen, Belgium, ²Department of OB/Gyn Antwerp University, Antwerp, Belgium, ³Vilnius University Institute of Biotechnology Department of Biothermodynamics and Drug Design, Vilnius, Latvia, ⁴Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands

P18 – Characterization of the vaginal microbiome of healthy reproductive-aged Brazilian women

Marconi C^{1,2}, Ravel J³, Lima M⁴, Carvalho N⁵, Alves R⁶, Leite S⁷, Parada C⁸, Silva M²

¹Federal University of Paraná, Sector of Biological Sciences,

Department of Basic Pathology, Curitiba, Brazil, ²São Paulo State University, Botucatu Medical School, Department of Pathology, Botucatu, Brazil, ³University of Maryland, School of Medicine, Institute for Genome Sciences, Baltimore, USA, ⁴Federal University of Paraíba, Center for Medical Sciences, Department of Obstetrics and Gynecology, Joao Pessoa, Brazil, ⁵Federal University of Paraná, Sector Medical Sciences, Department of Obstetrics and Gynecology, Curitiba, Brazil, ⁶Federal University of Goiás, School of Medicine, Department of Gynecology and Obstetrics, Goiania, Brazil, ⁷University of the State of Pará, Center for Biological and Health Sciences, Belém, Brazil, ⁸São Paulo State University, Botucatu Medical School, Department of Nursing, Botucatu, Brazil

P19 – Are BV pathologic core able to downregulate β defensins production to escape innate immunity?

Noda-Nicolau N¹, Morales J¹, Tronco J¹, Bastos L¹, Ferreira C¹, Polettini J², Marconi C³, Pinto G¹, Bolpetti A¹, Silva M¹

¹São Paulo State University (UNESP), Botucatu Medical School, Department of Pathology, Botucatu, Brazil, ²The University of Western São Paulo (UNOESTE), Presidente Prudente, Brazil, ³Department of

02nd ISIDOG CONGRESS

POSTER INDEX / ABSTRACTS

Basic Pathology, Setor de Ciências Biológicas, UFPR, Univ Federal do Paraná, Curitiba, Brazil

P20 – Posterior vestibulectomy in the treatment of localized provoked vulvodynia — A long-term follow-up study

Tommola P¹, Unkila-Kallio L¹, Paavonen J¹
¹Helsinki University Hospital, Espoo, Finland

P21 – Wet mount characterization of the vaginal flora of women with HIV

Vieira-baptista P¹, Lima-Silva J¹, Xavier J¹, Malheiro F¹, Melo C¹, Falcão V¹, Beires J¹, Donders G^{2,3,4}

¹Centro Hospitalar de São João, Porto, Portugal, ²Antwerp University Hospital, Antwerp, Belgium, ³Regional Hospital Heilig Hart, Tienen, Belgium, ⁴Femicare, Clinical Research for Women, Belgium

P22 – Non-response to maintenance treatment for recurrent Vulvovaginal Candidosis (RCVV) is not related to the impaired glucose metabolism

Grinceviciene S^{1,2}, Bellen G¹, Ruban K⁴, Donders G^{1,3}
¹Femicare vzw, Tienen, Belgium, ²Department of Biothermodynamics and Drug Design, Vilnius University Institute of Biotechnology, Vilnius, Latvia, ³Department of OB/Gyn, Antwerp University, Antwerp, Belgium

OC11 – Cervico-vaginal placental alpha-microglobulin-1 (PAMG-1) combined with cervical length accurately predict preterm birth in women with threatened preterm labor

Mueller M¹, Radan A¹, Heverhagen A¹, Polowy J¹, Simillion C², Raio L¹, Schleussner E³, Surbek D¹

¹Department of Obstetrics and Gynecology, University Hospital Bern and University of Bern, Bern, Switzerland, ²Department of Clinical Research, University of Bern, Bern, Switzerland, ³Department of Obstetrics and Gynecology, University Hospital, Jena, Germany

OC12 – Pregnant women with Cytomegalovirus infection — obstetrical and neonatal outcome

Ribeiro A¹, Pedrosa S, Boia M, Almeida M, Neto S, Oliveira M
¹Centro Hospitalar do Baixo Vouga, Portugal

P23 – Management of pregnancy and birth in HIV positive mothers – 20 years of experience in „Panait Sirbu” Clinical Hospital of Obstetrics & Gynecology, Bucharest

Mitran M^{1,2}, Puia S², Velicu O², Comandasu D², Bratila E^{1,2}
¹„Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania, ²„Panait Sirbu” Clinical Hospital of Obstetrics & Gynecology, Bucharest, Romania

P24 – Seroprevalence of Anti-Chlamydia trachomatis IGM in neonatal respiratory tract infections in Hungary, 2008-2016

Balla E¹, Petrovay F¹, Donders G^{2,3}

¹Department of Bacteriology II., National Public Health Institute, Budapest, Hungary, ²Femicare Clinical Research for Women, Tienen, Belgium, ³Department of Obstetrics and Gynecology, University Hospital Antwerp, Edegem, Belgium

P25 – Distribution of conjunctival Chlamydia trachomatis genotypes in ophthalmia neonatorum in Hungary, 2008-2016

Balla E¹, Petrovay F¹, Erdösi T², Donders G^{3,4}

¹Department of Bacteriology II., National Public Health Institute, Budapest, Hungary, ²Department of Phage and Molecular Typing, National Public Health Institute, Budapest, Hungary, ³Femicare Clinical Research for Women, Belgium, ⁴Department of Obstetrics and Gynecology, University Hospital Antwerp, Edegem, Belgium

P26 – Genital bacterial infection, potential cause of preterm delivery

Bogavac M¹, Ilic Đ¹, Ivanovic L¹, Novakovic Z²
¹University Of Novi Sad, Medical Faculty, Clinical Centre Vojvodina, Department Of Obstetrics And Gynecology Novi Sad, Se,

02nd ISIDOG CONGRESS

POSTER INDEX / ABSTRACTS

Serbia, ²Primary Helath Care Bac, Serbia, Bac, Serbia

P27 – Two cases of preterm premature rupture of membranes (pPROM) and preterm birth with different outcome: still a challenge for clinical management.

Falcone V¹, Pateisky P¹, Helmer H¹, Farr A¹, Kiss H¹, Petricevic L¹

¹Frauenheilkunde, Medizinische Universität Wien, Wien, Austria

P28 – Is bacterial surveillance of the upper and lower respiratory tract important in pediatric primary dyskinesia patients?

Diesner S¹, Falcone V², Nissen A¹, Bannert C¹, Gruber S¹, Nachbauer E¹, Renner S¹, Eiwegger T³, Szepefalusi Z¹

¹Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria, Wien, Austria, ²Department of Obstetrics and Gynecology, Medical University of Vienna, Austria, Wien, Austria, ³Division of Immunology and Allergy, Food allergy and Anaphylaxis Programm, The Department of Pediatrics, Hospital for Sick Children, The University of Toronto, Toronto, Canada

P29 – Evaluation of the vaginal flora in pregnant women with opioid-maintenance therapy: a matched case-control study

Farr A¹, Holzer I¹, Kiss H¹, Hagmann M¹, Husslein P¹, Petricevic L¹ ¹Medical University of Vienna, Vienna, Austria

P30 – Late Onset Candida Colonization and Preterm Birth

Holzer I¹, Farr A¹, Kiss H¹, Hagmann M², Petricevic L¹ ¹Division of Obstetrics and Fetomaternal Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, 1090, Austria, Wien, Austria, ²Section for Medical Statistics (IMS), Center of Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria,

P31 – Risk of vaginal infections at early gestation in patients with diabetic conditions: a retrospective cohort study

Marschalek J¹, Farr A¹, Kiss H¹, Hagmann M², Göbl C¹, Marschalek M¹, Petricevic L¹

¹Department of Obstetrics and Gynaecology, Medical University of Vienna, Wien, Austria, ²Section for Medical Statistics (IMS), Centre of Medical Statistics, Informatics and Intelligent Systems at the Medical University Vienna, Vienna, Austria

P32 – Prevalence and characteristics of active hepatitis B in pregnant

women in Switzerland – a survey from two sites

Mosimann B¹, Aebi-Popp K³, Fischer T², Gebhardt J⁵, Amylidi-Mohr S¹, Suter F³, Raio L², Kahlert C⁴, Surbek D¹

¹Department of Obstetrics and Gynecology, University Hospital and University of Bern, Bern, Switzerland, ²Frauenklinik Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Department of Infectious Diseases, University Hospital and University of Bern, Bern, Switzerland, ⁴Infektiologie Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Gynäkologie und Geburtshilfe Spital Wil, Wil, Switzerland

P33 – How reliable are WBC count and CRP to monitor for intra-amnionic infection?

Kiss H¹, Aulona G¹, Petricevic L¹, Pateisky P¹

¹Medizinische Universität Wien, Universitätsklinik für Frauenheilkunde, Wien, Austria

All abstracts are accessible via <http://mondial-congress.com/en/isidog17>

A printed abstract book is available at the registration counter.

Neu von Canesten gegen Scheidenpilz

1-Tages-Therapie
mit innovativer Weichkapsel

NEU

Weichkapsel

mit Gelatinehülle und
semi-flüssigem Kern

Wirkstoff: 0,5g Clotrimazol

diskret – effektiv – unkompliziert

REZEPTFREI



02nd ISIDOG CONGRESS

INVITED FACULTY INDEX

Clarke Emily, Solent NHS Trust, Portsmouth/United Kingdom

De Seta Francesco, University Of Trieste, Trieste/Italy

Depuydt Christophe, Aml - Sonic Healthcare Belgium, Antwerpen/Belgium

Donders Gilbert, University Hospital Antwerp, Vulvo-Vaginal Disease clinic, Antwerpen/Belgium

Farr Alex, Medical University of Vienna, Vienna/Austria

Greenhouse Peter, Weston Integrated Sexual Health Centre, Bristol/United Kingdom

Hay Phillip, St. George's Hospital, London/United Kingdom

Heczko Piotr, Jagiellonian University Medical College, Chair Of Microbiology, Krakow/Poland

Joura Elmar, Medical University Vienna, Vienna/Austria

Kiss Herbert, Medical University Vienna, Department of Obstetrics and Gynecology, Vienna/Austria

Lamont Ronald, Northwick Park and St Mark's NHS Trust, Department of Obstetrics and Gynaecology, London/UK

Larsson P-G, Skövde/Sweden

Martinez De Tejada Begonia, University Hospitals of Geneva, Geneva/Switzerland

Meijer Chris Jim, Vrije Universiteit Medical Center, Amsterdam/The Netherlands

Mendling Werner, Deutsches Zentrum Für Infektionen In Gynäkologie Und Geburtshilfe, Wuppertal/Germany

Oerlemans Eline, University of Antwerp, Antwerp/Belgium

Paavonen Jorma, University of Helsinki, Helsinki/Finland

Petricevic Ljubomir, Medical University Vienna, Department of Obstetrics and Gynecology, Vienna/Austria

Rakić Snežana, Ob/gyn Clinic Narodni Front, Belgrade/Serbia

Redlberger-Fritz Monika, Center Of Virology, Medical University Vienna, Vienna/Austria

Ruban Katerina, Femicare Vzw, Tienen/Belgium

Rumyantseva Tatiana, Moscow/Russian Federation

Schäfer Axel, Arbeitskreis Infektionen Und Sexualität, Berlin/Germany

Sobel Jack, Wayne State University School Of Medicine, Detroit, Michigan/United States

Stary Georg, Medical University Vienna, Vienna/Austria

Surbek Daniel, University Hospital Bern, Switzerland, Bern/Switzerland

ten Oever Jaap, Radboud University Medical center, Nijmegen/Netherlands

Ugwumadu Austin, St. George's University of London, London/United Kingdom

Viera Baptista Pedro, Lower Genital Tract Unit, Centro Hospitalar De São João, Porto/Portugal

Vossen Matthias Gerhard, Vienna/Austria

←Canesten® Clotrimazol 0,5 g Weichkapsel zur vaginalen Anwendung. Qualitative und quantitative Zusammensetzung:

1 Weichkapsel enthält 0,5 g Clotrimazol. Liste der sonstigen Bestandteile: 1 Weichkapsel enthält 0,5 g Clotrimazol. Liste der sonstigen Bestandteile: Zusammensetzung des Füllmaterials: Weißes Vaseline, dickflüssiges Paraffin. Zusammensetzung der trockenen Gelatinehülle: Gelatine, Glycerol, Gereinigtes Wasser, Titandioxid (E171), Chinolingelb (E104), Gelborange S (E110), Lecithin (E322), Triglyzeride, mittlere Ketten. Pharmakotherapeutische Gruppe: Gynäkologische Antinfektiva und Antiseptika, Imidazol Derivate ATC-Code: G01AF02. Anwendungsgebiete: Behandlung von Infektionen der Vagina und äußeren weiblichen Geschlechtsorgane verursacht durch Clotrimazol empfindliche Mikroorganismen wie Pilze (üblicherweise Candida). Gegenanzeigen: Überempfindlichkeit gegen Clotrimazol oder einen der genannten sonstigen Bestandteile. Inhaber der Zulassung: Bayer Austria Ges.m.b.H., Herbststraße 6 - 10, 1160 Wien. Rezeptpflicht/Apothekenpflicht: Rezeptfrei, apothekenpflichtig. Weitere Angaben zu Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Schwangerschaft und Stillzeit und Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation. Stand der Information: 09.2016

02nd ISIDOG CONGRESS

AUTHORS INDEX

Abstract Authors

A

Aebi-Popp, K
P32
Amylidi-Mohr, S
P32
Aleman, L
P03
Arendarski, P
P07
Almeida, M
OC12
Aulona, G
P33
Alves, R
P18

B

Bacalbasa, N
OC03
Berza, N
P02
Balla, E
P24, P25
Bogavac, M
P26
Balsyte, R.
P06a
Bohaltea, R
P06
Bannert, C
P28
Boia, M
OC12
Bastos, L
P19
Bolpetti, A
P19
Beert, J
OC01
Bosmans, E
OC01
Beires, J
P09, P21
Boř, M

P05
Bekos, C
OC02
Brand, S
P15
Bellen, G
OC06, OC08,
OC09, P16, P17
P22

Bratila, E
P06, P23
BERCEANU, C
P14
BRĂȚILĂ, E
P14

C

Carvalho, N
P18
Comandasu, D
P06, P23
Celiesiute, J.
P06a
COMANDAȘU, D
P14
CÎRSTOIU, M
P14
Cretoiu, D
OC03
Claes, I
OC06, OC09

D

Davidovic-Grigoraki, M
P10
Diesner, S
P28
Degenhardt, T
P15
Domig, K
OC05
Depuydt, C
OC01

Donders, G
OC01, OC06,
OC08, OC09,
P09, P16, P17,
P21, P22, P24,
P 25
de Sanjose, S
P03

E

Eglite, L
OC04, P04
Erdősi, T
P25
Eiwegger, T
P28

F

Falcão, V
P09, P21
Ferreira, C
OC10, P19
Falcone, V
P27, P28
Fischer, T
P32
Farr, A
OC05, P27, P29,
P30, P31

G

Gebhardt, J
P32
Grimm, C
OC02
Gensthaler, L
P03
Grinceviciene, S
P06a, P16, P17,
P22
Göbl, C
P31
Grincevicus, J.
P06a
Golan, M

P11
Grjunberga, V
P02
Golim, M
OC10
Gruber, S
P28

H

Hagmann, M
P29, P30, P31
Holzer, I
P29, P30
Helmer, H
P27
Horvat, R
OC02, P03
Heverhagen, A
OC11
Husslein, P
P29

I

Ilic, Đ
P26
Ivanovic, L
P26
Isajevs, S
P02

J

Jacquemyn, Y
OC08
Jermakova, I
OC04, P04
Jaeger, M
P17
Joura, E
OC02, P03

K

Kahlert, C
P32
Koch, M
OC07
Kanopiene, A.

P06a
Kokanov, D
P10
Kiss, H
OC05, P27, P29,
P30, P31, P33
Kroica, J
OC04, P04
Kneifel, W
OC05, P07
Kunicina, D
OC04, P04

L

Laue, C
P07
Liesegang, A
P07
Lebeer, S
OC06, OC09
Lima, M
P18
Leite, S
P18
Lima-Silva, J
P09, P21
Liepniece-Karele, I
OC04
Linnerth, B
P07

M

Machado, R
P12, P13
Meyndon-cix, S
OC08
Malheiro, F
P09, P21
MIHAI, D
P14
Mandic, A
P10

02nd ISIDOG CONGRESS

AUTHORS INDEX

- Mihajlovic, S**
P08
Marconi, C
OC10, P18, P19
Mijailovic, A
P08
Marschalek, J
OC05, P31
Milovanovic, Z
P08
Marschalek, M
OC05, P31
Mitran, M
P06, P14, P23
Martinez-de-Oliveira, J
P12, P13
Morales, J
P19
Matuliene, J.
P06a
Mosimann, B
P32
MEHEDINȚU, C
P14
Mueller, M
OC11
Melo, C
P09, P21
N
Nachbaur, E
P28
Noda-Nicolau, N
P19
Neto, S
OC12
Novak, J
OC10
Netea, M
P17
Novakovic, S
P08
Nikolic, M
P08
Novakovic, Z
P26
Nissen, A
P28
Nyrjesy, P
P15
O
Oerlemans, E
OC06, OC09
Oliveira, M
OC12
P
Paavonen, J
P20
Petroška, D
P02
Palmeira-de-Oliveira, A
P12, P13
Petrovay, F
P24, P25
Palmeira-de-Oliveira, R
P12, P13
Pils, S
P03
Pannenbeckers, A
P07
Pinto, G
P19
Papazova, E
P07
Plisko, O
OC04, P04
Parada, C
P18
Polettini, J
P19
Pateisky, P
P27, P33
Polowy, J
OC11
Pedrosa, S
OC12
Polterauer, S
OC02, P03
Person, K
P15
Pop, L
P01
Petricevic, L
OC05, P07, P08, P27, P29, P30, P31, P33
Puia, S
P23
R
Radan, A
OC11
Renner, S
P28
Raio, L
OC11, P32
Rezeberga, D
OC04, P04
Rakic, S
P08
Ribeiro, A
OC12
Ravel, J
P18
Ruban, K
OC06, P16, P22
Reinthaller, A
OC02
S
Salembier, G
OC01
Sobel, J
P15
Schleussner, E
OC11
Solajic, N
P10
Schneeweiss-Friedl, J
OC07
Stani, J
P03
Schotzinger, R
P15
Suciu, I
OC03, P01
Schrezenmeir, J
P07
Suciu, N
OC03, P01
Senfelde, I
P02
Sukovas, A.
P06a
Silva, M
OC10, P18, P19
Surbek, D
OC11, P32
Smillion, C
OC11
Suter, F
P32
Singer, C
OC05
Szefpalusi, Z
P28
Sivina, D
OC04, P04
T
Tavakkol, A
P15
Tommola, P
P20
ten Oever, J
P17
Tronco, J
P19
Toader, O
OC03, P01
U
Umek, W
OC07
Uspele, L
P02
Unkila-Kallio, L
P20
V
Vaitkiene, D.
P06a
Velicu, O
P06, P23
Vanden Broeck, D
OC01
Verstraete, L
OC01
Vangelov, M
P08
Vieira-baptista, P
P09, P21
Vanseviciute, R.
P06a
Vladareanu, R
P05
Veit-Rubin, N
OC07
Vladareanu, S
P05
W
Wittouck, S
OC06, OC09
Wuyts, S
OC06, OC09
X
Xavier, J
P09, P21
Z
Zecevic, N
P08
Žodžika, J
OC04, P02, P04

02nd ISIDOG CONGRESS

SCIENTIFIC INFORMATION

If you are a Chairperson

Please be at your session at least 15 minutes prior to the start of the session. We may remind you that speakers need to strictly observe the time schedule. Participants in the discussion should not speak before they are recognised.

If you are a Speaker

Presentation slides are to be prepared in the English language (exception: German Lectures). Only **PowerPoint presentations – format 16:9** – can be accepted.

- » For sessions starting at 08:30, PowerPoint presentations should be delivered on the previous day.
- » In order to avoid any delays, speakers are kindly requested to hand in their Power Point presentations on USB.
- » Changes in the presentation are NOT possible when uploading your presentation. Please make sure that you hand over the final version to the technician.
- » All PCs in the lecture rooms are installed with the operating system Windows 10 and are equipped with Microsoft Office 2016 (including PowerPoint 2016). The presentations will be projected from a projector to the screen. Double projections are not possible.

If you are a Abstract Presenter

Oral Communication and Poster Presentations have to be presented in a dedicated session. The schedule of all abstract presentations can be found on page 19-25.

Poster Presenters should **deliver their PowerPoint presentations at the technician's booth at the back of each session hall at least 1 hours prior to the start** of the respective session. Please note that technicians will only be available in break times for uploading the presentation. **Presenting time for abstract presenters:**

Oral Communication (OC): 10 minutes + 5 minutes discussion time

Poster Presentation (P): 5 minutes + 2 minutes discussion time

Time is strictly limited.

G Donders Femicare Awards

As a founding president, Gilbert Donders created an bi-annual award of 500 euro for 2 price winning abstracts presented in in the European ISIDOG congress. Selection of the best presentations (Oral communication and posters) will be done based on the independent opinion of the chairmen of the scientific sessions together with two elected Board and Scientific committee members and following strict evaluation rules. Awards will be announced after the Saturday afternoon session of the congress.

02nd ISIDOG CONGRESS

OFFICIAL NETWORKING PROGRAM

Thursday, October 26th, 2017

WELCOME RECEPTION

EXHIBITION AREA

Start 19:30

All participants of the 02nd ISIDOG CONGRESS 2017 are cordially invited to visit the exhibition in order to meet colleagues, faculty members, abstract presenters and industry representatives for scientific exchange.

Saturday, October 28th, 2017

NETWORKING EVENING

EMPEROR'S LODGE

Kaiserloge
Galopprennbahn Freudenau
Freudenau 65
1020 Vienna

19:30-22:30

Busses will depart at 18:30 in front of Palais Niederösterreich and at 18:50 at Hotel Regina.

All participants of the 02nd ISIDOG CONGRESS 2017 are invited to participate in the networking evening. Tickets for the networking evening can be purchased at the registration counter. Subject on availability.

02nd ISIDOG CONGRESS

EXHIBITION & SPONSORING

EXHIBITORS (listed in alphabetical order)

BAYER AUSTRIA GMBH	MEDINOVA AG
BioMS MOLECULAR SCIENCE GMBH	MERCK SHARP & DOHME GMBH
BIOSE	MONTAVIT GMBH
FERDINAND MENZL MEDIZINTECHNIK GMBH	MULTI-GYN
GERMANIA PHARMAZEUTIKA GESMBH	S.A.M. PHARMA GMBH
GREINER BIO-ONE	SEKISUI
KAYMOGYN GMBH	DIAGNOSTICS & FEMTEVA
INSTITUT ALLERGOSAN	SCHÜLKE

SPONSOR ACKNOWLEDGEMENTS (listed in alphabetical order)

BAYER AUSTRIA GMBH	GERMANIA PHARMAZEUTIKA GESMBH
BIOTEST AUSTRIA GMBH	HSO HEALTH CARE GMBH
DR. AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL	MEDINOVA AG
GEDEON RICHTER	PFIZER CORP AUSTRIA

EXHIBITION OPENING TIMES

THURSDAY, 26 TH OCTOBER 2017	09:00 – 20:00
FRIDAY, 27 TH OCTOBER 2017	08:00 – 17:30
SATURDAY, 28 TH OCTOBER 2017	08:00 – 17:00

02nd ISIDOG CONGRESS

INDUSTRY-SUPPORTED SESSIONS

Friday, October 27 th , 2017		 GERMANIA PHARMAZEUTIKA
INDUSTRY-SUPPORTED SESSION Germania Pharmazeutika GesmbH Chair: <i>Petricevic L. (AT), Girgis H. (FR)</i> Landtagssaal	12:15	Lcr Regenerans® in intimate care: the wonderful tale of a live biotherapeutic product <i>Girgis H. (FR)</i>
	12:45	L.casei rhamnosus LCR 35, Lcr Regenerans in clinical use <i>Petricevic L. (AT)</i>
Saturday, October 28 th , 2017		 medinova
INDUSTRY-SUPPORTED SESSION Medinova AG Chair: <i>Donders G. (BE)</i> Landtagssaal	12.15 – 12.25	Welcome and introduction Vaginal infections and their importance in daily practice of a gynecologist <i>Surbek D. (CH)</i>
	12.25 – 12.45	Improvement of abnormal vaginal flora in Ugandan women by self-testing and short use of intravaginal antimicrobials <i>Donders G. (BE)</i>
	12.45 – 13.05	Gynoflor lactobacillus is a bacteriocin producer strain: the evidence of its antimicrobial activity against genital microorganisms <i>Palmeira de Oliveira A. (PT)</i>



Fluomizin®


10 mg dequalinium chloride – vaginal tablets

for the treatment of bacterial vaginosis

- safe for use in pregnancy and lactation ^{1,2,3,4,5}
- antimicrobial activity against all relevant pathogens in vaginal infections ^{1,6}
- also active against *Atopobium vaginae* ⁷
- no reported development of resistance of micro-organisms ¹



Astarte goes international



We are at the beginning of a rethinking of health issues. Probiotics stand for a real alternative, prevention, and supplementation in many areas. We see our already many cooperations and partnerships as an indicator for further promising development in the probiotic field.

What about your Country?

Please contact HSO Health Care GmbH
Tuchlauben 18
1010 Vienna
Austria
Tel.: +43/1/2350780
office@hso.at
www.astarte-probiotics.com

Good bacteria promotes
women's health

